Posted by Michael Wonder on 01 May 2024
Selpercatinib for the treatment of patients with advanced thyroid cancer with RET alterations that has not been treated with systemic therapy
1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of selpercatinib in the NHS in England.
For the time being, selpercatinib is not recommended for the treatment of patients 12 years and older with advanced RET mutant medullary thyroid cancer that has not been treated with systemic therapy and patients 12 years and older with advanced RET fusion positive thyroid cancer that has not been treated with systemic therapy and is refractory to or not suitable for radioactive iodine.
